West Pharmaceutical Services, Inc. (NYSE:WST) Receives $355.55 Average PT from Brokerages

West Pharmaceutical Services, Inc. (NYSE:WST) has earned an average recommendation of “Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $363.1667.

WST has been the subject of a number of analyst reports. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Evercore restated an “outperform” rating and issued a $410.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 6th. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research report on Monday. They issued an “outperform” rating and a $447.00 price target on the stock. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Finally, Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th.

West Pharmaceutical Services Price Performance

Shares of WST opened at $362.08 on Friday. The business’s fifty day moving average is $332.06 and its 200 day moving average is $284.28. West Pharmaceutical Services has a 12-month low of $206.80 and a 12-month high of $367.66. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. The stock has a market cap of $25.58 billion, a P/E ratio of 48.41, a P/E/G ratio of 2.91 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.67 million. During the same quarter in the previous year, the business posted $1.45 EPS. West Pharmaceutical Services’s quarterly revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Sell-side analysts anticipate that West Pharmaceutical Services will post 8.6 earnings per share for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In related news, CAO Chad Winters sold 896 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by insiders.

Institutional Trading of West Pharmaceutical Services

Several institutional investors and hedge funds have recently made changes to their positions in WST. Empowered Funds LLC grew its position in West Pharmaceutical Services by 16.1% in the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after purchasing an additional 224 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after buying an additional 1,307 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after buying an additional 157 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 197 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock worth $10,137,000 after buying an additional 29,067 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.